Multidisciplinary treatment of gastrointestinal stromal tumors.
Gastrointestinal stromal tumor (GIST) has been recognized as a unique tumor only in the last decade. Although rare as a clinical entity, there is much interest in the pathology and treatment because the KIT protooncogene mutation common to most GISTs can be inhibited by imatinib mesylate. Diagnosing and treating GIST requires a multidisciplinary approach, given the combination of pathologic and radiographic evaluation, surgical treatment, and oncologic care required to successfully treat patients with GIST.
Kingham
T Peter
TP
Department of Surgery, Memorial Sloan-Kettering Cancer Center, 303 E. 60th Street, Apt 28E, NY, NY 10022, USA. kinghamt@mskcc.org
DeMatteo
Ronald P
RP
D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D017115:Catheter Ablation; D003131:Combined Modality Therapy; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000601:surgery; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D010879:Piperazines / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D016019:Survival Analysis
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit